Apalutamide toxicity and tolerability: A real-world multicentre experience in metastatic hormone-sensitive prostate cancer (MHSPC) in the United Kingdom (UK).

被引：0
|
作者：
Ramamurthy, Sindhu
Elumalai, Thiraviyam
Pearson, Rachel
Bolnykh, Iakov
Muhammad-Afzal, Tehreem
Olukiran, Gbenro
Arora, Ananya
Bradley, Gay
Taft, Kate
Myint, Nayan Lin
Htike, Ei The
Ince, Will
Jiang, Xue Yan
机构：
[1] United Lincolnshire Hosp NHS Trust, Lincoln, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge, England
[3] Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[4] United Lincolnshire Hosp NHS Trust, Grantham, England
[5] Univ Cambridge, Sch Med, Cambridge, England
[6] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-2494-5577-5578; 613-615-646-3281-7408-2638; 261-492-199; 130-3426-5390-2622; 130-3426-3529; 283-2494; 613-302-309; 6; 5; 4; 3; 2; 1917; 8;
D O I：
10.1200/JCO.2024.42.4_suppl.107
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [2] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [3] Does use of apalutamide enhance outcomes in combination with radiotherapy in metastatic hormone-sensitive prostate cancer? A real-world experience from the UK.
    Das, Prantik
    Sharma, Anand
    Vengalil, Salil
    Khan, Yakhub
    Lim, JunHao
    Elmasry, Abdelfattah
    Mohammed, Rania
    Ghose, Aruni
    Bandyopadhyay, Seheli
    Nillegoda, Hasanthi
    Baraka, Bahaaeldin
    Tasmia, Syeda
    Mathiyalagan, Navin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 73 - 73
  • [4] Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study
    Lopez-Abad, Alicia
    Belmonte, Mario
    Backhaus, Miguel Ramirez
    Gomez, Gerardo Server
    Avellaneda, Enrique Cao
    Alarcon, Cristobal Moreno
    Cubillana, Pedro Lopez
    Gimenez, Pablo Yago
    Rodriguez, Pedro de Pablos
    Fita, Maria Jose Juan
    Duran, Miguel angel Climent
    Ruiz, Iris Guardiola
    Crespo, Natalia Vidal
    Aviles, Juan Moreno
    Martinez-Valls, Pablo Luis Guzman
    Gonzalez, Pedro angel Lopez
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (20)
  • [5] Triplet therapy in metastatic hormone-sensitive prostate cancer: A real-world Indian multicentre study.
    Mondal, Debapriya
    Roy, Somnath
    Bhattacharjee, Arnab
    Roy, Rakesh
    Meyur, Suman
    Biswas, Bivas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France, China and Japan
    Goebell, P. J.
    Shah, R.
    Raina, R.
    Rege, S.
    Chen, S. L.
    Lee, V. E.
    Waldeck, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S660 - S661
  • [7] LACK OF CONCORDANCE BETWEEN REAL-WORLD TREATMENT PATTERNS AND CLINICAL GUIDELINE RECOMMENDATIONS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) PATIENTS
    Goebell, P. J.
    Shah, R.
    Raina, R.
    Rege, S.
    Chen, S.
    Partridge, J.
    Waldeck, R.
    VALUE IN HEALTH, 2022, 25 (07) : S497 - S497
  • [8] QUALITATIVE EXPLORATION OF THE REAL-WORLD EXPERIENCES OF MEN RECEIVING OR REFUSING CHEMOTHERAPY (DOCETAXEL) FOR THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
    Ito, T.
    Grant, L.
    Mills, A.
    Heselwood, A.
    Gater, A.
    VALUE IN HEALTH, 2017, 20 (09) : A450 - A450
  • [9] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
  • [10] DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA
    Yu, M.
    Duan, X.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    VALUE IN HEALTH, 2021, 24 : S39 - S40
12345